Literature DB >> 18581511

Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies.

Edie Y Chan1, Anne M Larson, Oren K Fix, Matthew M Yeh, Adam E Levy, Ramasamy Bakthavatsalam, Jeffrey B Halldorson, Jorge D Reyes, James D Perkins.   

Abstract

The recurrence of hepatocellular carcinoma (HCC) is a major cause of mortality for patients transplanted with HCC. There currently exists no standard method for identifying those patients with a high risk for recurrence. Identification of factors leading to recurrence is necessary to develop an efficient surveillance protocol and address new potential adjuvant therapies. We conducted a retrospective review of 834 consecutive liver transplants from 1/1/1996 to 12/31/2005 (mean follow-up 1303 +/- 1069 days) at one institution and 352 consecutive transplants from 1/2/2002 to 12/31/2005 (mean follow-up 836 +/- 402 days) at a second institution. The test cohort comprised patients identified with HCC in their explanted livers from 1/1/2001 to 12/31/2005 at the first institution. Explant pathology and donor and recipient characteristics were reviewed to determine factors associated with HCC recurrence. These predictors were validated in the remaining liver transplant recipients. The test cohort had 116 patients with findings of HCC in their explanted livers. Twelve patients developed recurrent HCC. Stepwise logistic regression identified 4 independent significant explant factors predictive of recurrence. Size of one tumor (>4.5 cm), macroinvasion, and bilobar tumor were positive predictors of recurrence, whereas the presence of only well-differentiated HCC was a negative predictor. Designating each significant factor with points in relation to its odds ratio, a Predicting Cancer Recurrence Score (PCRS) with results ranging from -3 to 6 was developed that accurately determined risk of recurrence. These findings were then applied to the two validation cohorts, which confirmed the high predictive value of this model. In conclusion, patients transplanted for HCC with a PCRS of < or =0 have a low risk of recurrence. Patients with a PCRS of 1 or 2 have a moderate risk of recurrence, and those with a PCRS of > or =3 have a high risk for recurrence.

Entities:  

Mesh:

Year:  2008        PMID: 18581511     DOI: 10.1002/lt.21449

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  12 in total

1.  Current status of therapy for hepatocellular carcinoma.

Authors:  Kathleen E Corey; Daniel S Pratt
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

2.  Liver transplantation for hepatocellular carcinoma: are international guidelines possible?

Authors:  Tammy T Hshieh; Vinay Sundaram
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

Review 3.  What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?

Authors:  Christophe Duvoux; Tetsuya Kiuchi; Bernhard Pestalozzi; Ronald Busuttil; Rebecca Miksad
Journal:  Liver Transpl       Date:  2011-10       Impact factor: 5.799

4.  Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation.

Authors:  E Dudley Colhoun; C Gunnar Forsberg; Kenneth D Chavin; Prabhakar K Baliga; David J Taber
Journal:  Surgery       Date:  2016-10-19       Impact factor: 3.982

Review 5.  Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation.

Authors:  Helena Degroote; Anja Geerts; Xavier Verhelst; Hans Van Vlierberghe
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

Review 6.  Hepatocellular carcinoma: A comprehensive review.

Authors:  Lisa P Waller; Vrushak Deshpande; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2015-11-18

7.  Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.

Authors:  Nadim Mahmud; Abraham Shaked; Kim M Olthoff; David S Goldberg
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

8.  Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma.

Authors:  Gregory C Connolly; Saman Safadjou; Randeep Kashyap; Rui Chen; Mark S Orloff; Aram F Hezel
Journal:  BMC Gastroenterol       Date:  2013-01-14       Impact factor: 3.067

9.  Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation.

Authors:  Trina Das; Deborah L Diamond; Matthew Yeh; Sajida Hassan; Janine T Bryan; Jorge D Reyes; James D Perkins
Journal:  J Transplant       Date:  2013-11-26

Review 10.  Living donor liver transplantation for patients with hepatocellular carcinoma.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Liver Cancer       Date:  2014-05       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.